China’s pharmaceutical exports to Brazil reached US$ 449 million in 2020 according to global customs data, up 197% over the same period of last year, which brings China to be the fifth largest pharmaceutical supplier to Brazil.
China’s pharmaceutical exports maintains a good situation while the global pharmaceutical trade being hit by the COVID-19 epidemic, mainly due to the fact that China was able to control the spread of the epidemic as quickly as possible. The stable production capacity in China was in sharp contrast to the blocked supply chain line overseas.
Brazil is a major emerging pharmaceutical market, along with China, India, Russia, Turkey and Mexico. Brazil became the seventh largest pharmaceutical market in the world in 2018, with a expected market size of 39-43 billion USD by 2023, making it the fifth largest pharmaceutical market in the world.The sale of Brazil’s original drug market is just over 20%, and quantity of sale is less than 5%. Non-patent brand drugs and generic generics occupy about 20% of the market share, and the OTC drug market is with huge potential.
Brazil mainly do domestic production for human drugs due to the local policy, only a small proportion relying on imports. However, the APIs used for human drugs are mainly by import. According to a research, most of the APIs in Brazil’s pharmaceutical factory is imported from Germany, China, the United States, India, Switzerland, Italy, France, Argentina and other countries, only a few excipients are produced locally.